Brokers Offer Predictions for Repare Therapeutics Inc.’s FY2028 Earnings (NASDAQ:RPTX)

Repare Therapeutics Inc. (NASDAQ:RPTX) – Investment analysts at Capital One Financial upped their FY2028 earnings estimates for Repare Therapeutics in a report released on Thursday, August 8th. Capital One Financial analyst T. Chiang now forecasts that the company will post earnings of $0.43 per share for the year, up from their prior forecast of $0.35. The consensus estimate for Repare Therapeutics’ current full-year earnings is ($2.39) per share.

Other research analysts have also recently issued research reports about the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a research note on Wednesday, June 5th. Bloom Burton upgraded Repare Therapeutics from an “accumulate” rating to a “buy” rating in a report on Friday, April 19th. Finally, Lifesci Capital upgraded shares of Repare Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $17.33.

Repare Therapeutics Stock Performance

NASDAQ:RPTX opened at $2.96 on Monday. Repare Therapeutics has a twelve month low of $2.78 and a twelve month high of $13.85. The firm’s fifty day simple moving average is $3.55 and its 200 day simple moving average is $4.39.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.03. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $4.02 million.

Institutional Trading of Repare Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. bought a new stake in shares of Repare Therapeutics in the 4th quarter worth about $110,000. SRS Capital Advisors Inc. raised its stake in Repare Therapeutics by 100.0% during the fourth quarter. SRS Capital Advisors Inc. now owns 10,000 shares of the company’s stock valued at $73,000 after buying an additional 5,000 shares in the last quarter. Jump Financial LLC bought a new position in Repare Therapeutics during the 4th quarter worth approximately $289,000. BVF Inc. IL grew its position in shares of Repare Therapeutics by 24.6% in the 4th quarter. BVF Inc. IL now owns 10,333,600 shares of the company’s stock worth $75,435,000 after acquiring an additional 2,041,612 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Repare Therapeutics by 53.5% in the 1st quarter. Acadian Asset Management LLC now owns 133,893 shares of the company’s stock valued at $625,000 after acquiring an additional 46,648 shares during the last quarter. 85.09% of the stock is owned by institutional investors and hedge funds.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.